---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-113606"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:50:12.310776+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Nektar Therapeutics Chief Legal Officer Mark A. Wilson to Depart; Elizabeth Zhang to Succeed

## Summary
- Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025.
- Elizabeth Zhang, Vice President of Legal and Corporate Counsel, will take over Wilson's responsibilities.
- Zhang joined Nektar in 2021 and previously worked at Cravath, Swaine & Moore and Gibson, Dunn & Crutcher.
- Zhang holds a BA from Harvard College, an MS from the University of Oxford, and a JD from Harvard Law School.
- Wilson's departure is not the result of any disagreement with Nektar on operations, policies, or practices.

## SEC filing metadata
- accession: 0001213900-25-113606
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025113606/0001213900-25-113606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025113606/ea0266707-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-113606
- JSON: https://secwatch.observer/filing/0001213900-25-113606.json
- Plain text: https://secwatch.observer/filing/0001213900-25-113606.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.